{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T16:53:07Z","timestamp":1772988787166,"version":"3.50.1"},"reference-count":16,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mocravimod, a novel immunomodulator targeting sphingosine\u20101\u2010phosphate receptor (S1PR), is being developed as a maintenance treatment for patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Preclinical data suggested that cytochrome (CYP) 3A4 is the primary enzyme involved in mocravimod metabolism. In vitro data showed that both mocravimod and its active metabolite mocravimod\u2010phosphate are substrates for breast cancer resistance protein (BCRP) and P\u2010glycoprotein (P\u2010gp) but not for organic\u2010anion\u2010transporting polypeptides (OATP1B1 and OATP1B3). As\u00a0mocravimod is co\u2010administered with CYP3A4 inhibitors such as azoles or cyclosporin, the potential for drug\u2013drug interactions (DDIs) was evaluated. In addition, the effect of BCRP, P\u2010gp, and OATP via cyclosporin co\u2010administration was assessed. Two open\u2010label, two\u2010period, fixed\u2010sequence studies were conducted in healthy subjects to evaluate the DDI potential of mocravimod and 1) itraconazole, a dual CYP3A4\/P\u2010gP inhibitor, or 2) cyclosporin, a moderate inhibitor of CYP3A4 and P\u2010gp, BCRP, OATP1B1, and OATP1B3. Safety and tolerability were also monitored. The PK of mocravimod and mocravimod\u2010phosphate were bioequivalent with or without co\u2010administration of multiple doses of itraconazole and a moderate interaction is observed when co\u2010administered with cyclosporin. The most commonly\u2010reported treatment\u2010emergent adverse events were bradycardia and decreased lymphocyte count, which are expected side effects for S1PR modulators.<\/jats:p>","DOI":"10.1002\/cpdd.1622","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T18:50:19Z","timestamp":1761763819000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical assessment of mocravimod as a victim of drug\u2013drug interactions via CYP3A4 metabolism and transporters"],"prefix":"10.1002","volume":"15","author":[{"given":"Dymphy R.","family":"Huntjens","sequence":"first","affiliation":[{"name":"Priothera SAS  Saint\u2010Louis France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Oehen","sequence":"additional","affiliation":[{"name":"Priothera SAS  Saint\u2010Louis France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Kueenburg","sequence":"additional","affiliation":[{"name":"Priothera SAS  Saint\u2010Louis France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"e_1_2_13_2_1","volume-title":"The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies","author":"Sureda A","year":"2025"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.119172"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2014.945988"},{"key":"e_1_2_13_5_1","unstructured":"U. S. Food and Drug Administration:Clinical drug interaction studies: cytochrome P450 enzyme\u2010 and transporter\u2010mediated drug interactions guidance for industry. January 2020. Accessed August 20 2025.https:\/\/www.fda.gov\/drugs\/guidance\u2010compliance\u2010regulatory\u2010information\/guidances\u2010drugs"},{"key":"e_1_2_13_6_1","unstructured":"European Medicines Agency:Guideline on the investigation of drug interactions CPMP\/EWP\/560\/95\/Rev. 1 Corr. 2. January 1 2013.Accessed August 20. 2025.https:\/\/www.ema.europa.eu\/en\/investigation\u2010drug\u2010interactions\u2010scientific\u2010guideline"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11020075"},{"key":"e_1_2_13_8_1","unstructured":"U. S. Food and Drug Administration:GILENYA (fingolimod) capsules for oral use initial U.S. Novartis.2010. Accessed August 20 2025.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022527s000lbl.pdf"},{"key":"e_1_2_13_9_1","unstructured":"Summary of product characteristics Sporanox\u00ae 100\u00a0mg capsule from r\u00e9sum\u00e9 des caract\u00e9ristiques du produit \u2010 SPORANOX 100\u00a0mg g\u00e9lule \u2010 base de donn\u00e9es publique des m\u00e9dicaments (medicaments.gouv.fr). Accessed August 20 2025.https:\/\/base\u2010donnees\u2010publique.medicaments.gouv.fr\/medicament\/62469613\/extrait"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.562"},{"key":"e_1_2_13_11_1","unstructured":"Summary of product characteristics NEORAL\u00ae from r\u00e9sum\u00e9 des caract\u00e9ristiques du produit \u2010 NEORAL 100\u00a0mg capsule molle \u2010 base de donn\u00e9es publique des m\u00e9dicaments (medicaments.gouv.fr). Accessed August 20 2025.https:\/\/base\u2010donnees\u2010publique.medicaments.gouv.fr\/medicament\/67194943\/extrait"},{"key":"e_1_2_13_12_1","unstructured":"U. S. Food and Drug Administration:Statistical approaches to establishing bioequivalence. February 2001. Accessed August 20 2025.https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/statistical\u2010approaches\u2010establishing\u2010bioequivalence"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-015-9829-2"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13577"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342010-00003"},{"key":"e_1_2_13_16_1","unstructured":"ICON development solutions NONMEM users guide introduction to NONMEM. April 7 2017. Accessed August 20 2025.https:\/\/nmhelp.tingjieguo.com\/guides\/intro7.pdf"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.878"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1622","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpdd.1622","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1622","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T11:39:46Z","timestamp":1772969986000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.1622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1002\/cpdd.1622"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.1622","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"2025-08-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e1622"}}